FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378071617> ?p ?o ?g. }

• W4378071617 endingPage "100502" @default.
• W4378071617 startingPage "100502" @default.
• W4378071617 abstract "Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). However, testing for albuminuria among patients with T2D is substantially underutilized in clinical practice; many patients with CKD go unrecognized. For patients with T2D at high cardiovascular risk, or with established CVD, the glucagon-like peptide-1 receptor agonists (GLP1-RA) have been shown to reduce ASCVD in cardiovascular outcome trials, while potential kidney outcomes are being explored. A recent meta-analysis found that GLP1-RA reduced 3-point major adverse cardiovascular events by 14% [HR, 0.86 (95% CI, 0.80–0.93)] in patients with T2D. The benefits of GLP1-RA to reduce ASCVD were at least as large among people with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. GLP1-RA also conferred a 21% reduction in the composite kidney outcome [HR, 0.79 (0.73–0.87)]; however, this result was achieved largely through reduction in albuminuria. It remains uncertain whether GLP1-RA would confer similar favorable results for eGFR decline and/or progression to end-stage kidney disease. Postulated mechanisms by which GLP1-RA confer protection against CVD and CKD include blood pressure lowering, weight loss, improved glucose control, and decreasing oxidative stress. Ongoing studies in T2D and CKD include a kidney outcome trial with semaglutide (FLOW, NCT03819153) and a mechanism of action study (REMODEL, NCT04865770) examining semaglutide's effect on kidney inflammation and fibrosis. Ongoing cardiovascular outcome studies are examining an oral GLP1-RA (NCT03914326), GLP1-RA in patients without T2D (NCT03574597), and dual GIP/GLP1-RA agonists (NCT04255433); the secondary kidney outcomes of these trials will be informative. Despite their well-described ASCVD benefits and potential kidney protective mechanisms, GLP1-RA remain underutilized in clinical practice. This highlights the need for cardiovascular clinicians to influence and implement use of GLP1-RA in appropriate patients, including those with T2D and CKD at higher risk for ASCVD." @default.
• W4378071617 created "2023-05-25" @default.
• W4378071617 creator A5009544182 @default.
• W4378071617 creator A5012514694 @default.
• W4378071617 creator A5020174004 @default.
• W4378071617 creator A5036283255 @default.
• W4378071617 date "2023-06-01" @default.
• W4378071617 modified "2023-10-16" @default.
• W4378071617 title "Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection" @default.
• W4378071617 cites W1932640386 @default.
• W4378071617 cites W2004409542 @default.
• W4378071617 cites W2040299750 @default.
• W4378071617 cites W2043575472 @default.
• W4378071617 cites W2044773944 @default.
• W4378071617 cites W2056976690 @default.
• W4378071617 cites W2111663222 @default.
• W4378071617 cites W2114598208 @default.
• W4378071617 cites W2116077357 @default.
• W4378071617 cites W2136259411 @default.
• W4378071617 cites W2150959326 @default.
• W4378071617 cites W2158530640 @default.
• W4378071617 cites W2282578582 @default.
• W4378071617 cites W2306319461 @default.
• W4378071617 cites W2425644022 @default.
• W4378071617 cites W2475261460 @default.
• W4378071617 cites W2475954707 @default.
• W4378071617 cites W2519510391 @default.
• W4378071617 cites W2574032118 @default.
• W4378071617 cites W2607109151 @default.
• W4378071617 cites W2750733474 @default.
• W4378071617 cites W2754041380 @default.
• W4378071617 cites W2808008353 @default.
• W4378071617 cites W2894746763 @default.
• W4378071617 cites W2902989158 @default.
• W4378071617 cites W2904356389 @default.
• W4378071617 cites W2939222610 @default.
• W4378071617 cites W2947335986 @default.
• W4378071617 cites W2948612418 @default.
• W4378071617 cites W2954229159 @default.
• W4378071617 cites W2968073288 @default.
• W4378071617 cites W2970412630 @default.
• W4378071617 cites W2981486868 @default.
• W4378071617 cites W2996211773 @default.
• W4378071617 cites W3001507139 @default.
• W4378071617 cites W3021898772 @default.
• W4378071617 cites W3036099596 @default.
• W4378071617 cites W3042751537 @default.
• W4378071617 cites W3047536039 @default.
• W4378071617 cites W3088173406 @default.
• W4378071617 cites W3092379111 @default.
• W4378071617 cites W3094429645 @default.
• W4378071617 cites W3102119644 @default.
• W4378071617 cites W3112069718 @default.
• W4378071617 cites W3118994355 @default.
• W4378071617 cites W3132834236 @default.
• W4378071617 cites W3134100899 @default.
• W4378071617 cites W3153705318 @default.
• W4378071617 cites W3158225292 @default.
• W4378071617 cites W3175947914 @default.
• W4378071617 cites W3177365549 @default.
• W4378071617 cites W3177393241 @default.
• W4378071617 cites W3178715673 @default.
• W4378071617 cites W3193297191 @default.
• W4378071617 cites W3195404919 @default.
• W4378071617 cites W3210322431 @default.
• W4378071617 cites W4200439235 @default.
• W4378071617 cites W4206077470 @default.
• W4378071617 cites W4206445899 @default.
• W4378071617 cites W4225655571 @default.
• W4378071617 cites W4306783500 @default.
• W4378071617 cites W4306783667 @default.
• W4378071617 cites W4308183941 @default.
• W4378071617 cites W4318980736 @default.
• W4378071617 doi "https://doi.org/10.1016/j.ajpc.2023.100502" @default.
• W4378071617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37313358" @default.
• W4378071617 hasPublicationYear "2023" @default.
• W4378071617 type Work @default.
• W4378071617 citedByCount "1" @default.
• W4378071617 crossrefType "journal-article" @default.
• W4378071617 hasAuthorship W4378071617A5009544182 @default.
• W4378071617 hasAuthorship W4378071617A5012514694 @default.
• W4378071617 hasAuthorship W4378071617A5020174004 @default.
• W4378071617 hasAuthorship W4378071617A5036283255 @default.
• W4378071617 hasBestOaLocation W43780716171 @default.
• W4378071617 hasConcept C126322002 @default.
• W4378071617 hasConcept C134018914 @default.
• W4378071617 hasConcept C159641895 @default.
• W4378071617 hasConcept C2776174234 @default.
• W4378071617 hasConcept C2777180221 @default.
• W4378071617 hasConcept C2778653478 @default.
• W4378071617 hasConcept C2780091579 @default.
• W4378071617 hasConcept C2781308992 @default.
• W4378071617 hasConcept C2909862629 @default.
• W4378071617 hasConcept C555293320 @default.
• W4378071617 hasConcept C71924100 @default.
• W4378071617 hasConceptScore W4378071617C126322002 @default.
• W4378071617 hasConceptScore W4378071617C134018914 @default.
• W4378071617 hasConceptScore W4378071617C159641895 @default.

• next